Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
| Revenue (TTM) | $879.95M |
| Gross Profit (TTM) | $445.10M |
| EBITDA | $414.16M |
| Operating Margin | 37.50% |
| Return on Equity | 53.60% |
| Return on Assets | 28.60% |
| Revenue/Share (TTM) | $131.49 |
| Book Value | $49.81 |
| Price-to-Book | 3.90 |
| Price-to-Sales (TTM) | 1.37 |
| EV/Revenue | 1.698 |
| EV/EBITDA | 5.12 |
| Quarterly Earnings Growth (YoY) | 95.90% |
| Quarterly Revenue Growth (YoY) | 2.20% |
| Shares Outstanding | $6.88M |
| Float | $4.22M |
| % Insiders | 29.06% |
| % Institutions | 42.52% |
Volatility is currently expanding
Nutex Health is rated Buy, with a DCF-based price target of $199.31, offering 19.8% upside from $166.40. NUTX's revenue surged from $247.6M in FY2023 to $880.0M TTM ended March 31, 2026, driven by effective use of the No Surprises Act's IDR process. Liquidity and leverage metrics have improved, with debt-to-equity falling below 1.0 and the current ratio at 3.1 in the TTM period.
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders.
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
NEW YORK, April 29, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Nutex Health caused the company to misrepresent or fail to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, public statements were materially false and misleading at all relevant times.
HOUSTON, April 22, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the first fiscal quarter ended March 31, 2026, on Thursday, April 30, 2026 after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day.
